Medicine and Dentistry
Radiation Therapy
100%
Non Small Cell Lung Cancer
77%
Overall Survival
69%
Neoplasm
64%
Stereotactic Body Radiation Therapy
39%
Malignant Neoplasm
38%
Hepatocellular Carcinoma
37%
Progression Free Survival
30%
Positron Emission Tomography
23%
Chemoradiation Therapy
22%
Disease
20%
Positron Emission Tomography
19%
Chemoradiotherapy
19%
COVID-19
18%
Meta-Analysis
18%
Hazard Ratio
16%
Brachytherapy
16%
Head and Neck Cancer
16%
Systematic Review
15%
Immunotherapy
15%
Survival Rate
15%
Fluorodeoxyglucose F 18
14%
Pancreas Cancer
14%
Clinical Trial
13%
Lung Cancer
13%
Proportional Hazards Model
13%
Proton Therapy
13%
Prostate Cancer
12%
Lung Tumor
10%
Non-Small Cell Lung Cancer
10%
Patient Population
10%
Drug Megadose
9%
Hypofractionated Radiotherapy
9%
Transcatheter Arterial Chemoembolization
9%
Treatment Planning
9%
Socioeconomic Status
9%
Prognostic Factor
9%
Recurrent Disease
9%
Breast Cancer
8%
Oncology
8%
Patient-Reported Outcome
8%
External Beam Radiotherapy
8%
Biological Marker
8%
Adverse Event
7%
Wearable Sensor
7%
Decision Making
7%
Re-Irradiation
7%
Survival Analysis
7%
Neutrophil
7%
Lymphocyte
7%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
72%
Chemoradiation Therapy
59%
Overall Survival
53%
Neoplasm
40%
Progression Free Survival
38%
Disease
27%
Prostate Cancer
25%
Malignant Neoplasm
23%
Fluorodeoxyglucose F 18
19%
Liver Cell Carcinoma
18%
Lung Cancer
14%
Survival Rate
14%
Chemotherapy
12%
Durvalumab
10%
Gastrointestinal Toxicity
9%
Pancreas Cancer
9%
Disease Exacerbation
9%
Clinical Trial
8%
Immunotherapy
7%
Biological Marker
7%
Prostate Specific Antigen
7%
Therapeutic Window
6%
Adverse Event
6%
Rectum Cancer
6%
Esophagitis
5%
Solid Malignant Neoplasm
5%
Recurrent Disease
5%
Lung Tumor
5%
Keyphrases
Radiation Therapy
23%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
20%
Radiotherapy
16%
Chemoradiotherapy
15%
Non-small Cell Lung Cancer (NSCLC)
14%
Overall Survival
13%
Progression-free Survival
12%
Durvalumab
9%
PET Metrics
9%
Stereotactic Body Radiation Therapy
9%
Financial Toxicity
9%
Hepatocellular Carcinoma
9%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
9%
Head-and-neck Cancer
9%
Patient-generated Health Data
7%
Neutrophil-to-lymphocyte Ratio
7%
Prognostic Value
7%
Metabolic Tumor Volume
6%
Targeted Therapy
6%
Interocular
6%
Definitive Chemoradiotherapy (dCRT)
6%
Activity Monitoring
5%
National Cancer Database
5%
Cardiac Irradiation
5%